27th Jan 2014 09:57
LONDON (Alliance News) - Allergy Therapeutics PLC said Monday that results from its Phase IIb clinical trial of its Pollinex Quattro ragweed allergy treatment have been published in the Journal of Allergy and Clinical Immunology.
The trial showed that the treatment was safe and effective in reducing the common symptoms of an allergic response to ragweed pollen, Allergy Therapeutics said.
Shares in the allergy vaccine company were trading down 3.0% at 8.00 pence Monday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Allergy Thera.